Harnessing the power of upstream platform integration to accelerate biopharma innovation

Learn how Syngene’s integrated strategy can enhance your mAb production capabilities.

Oct. 21, 2024

PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug

European regulators have for the fourth time issued a negative opinion on PTC's Translarna. Elsewhere, Amylyx read out data and Leqembi hit a roadblock in Australia.

By BioPharma Dive staff • Oct. 18, 2024

Explore the Trendline➔

Top 5 stories from BioPharma Dive

Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.

By BioPharma Dive staff

After rejections, AbbVie secures approval for Parkinson’s drug

Vyalev’s clearance is the second victory for AbbVie in Parkinson’s this year, following an April readout for a drug acquired through its Cerevel buyout.

By Jacob Bell • Oct. 17, 2024

Sanofi, expanding in radiopharma, strikes a joint venture deal

The French drugmaker will invest 300 million euros into a new entity that will develop lead isotope-based therapies for cancer under the Orano Med brand.

By Ned Pagliarulo • Oct. 17, 2024

GSK claims Moderna infringed mRNA vaccine patents

The pharma’s lawsuit focuses on scientific work that helped clear the path for creating mRNA vaccines to fight the COVID-19 pandemic.

By Kristin Jensen • Oct. 16, 2024

Tremfya, Carvykti sales grow as J&J prepares for Stelara patent loss

Biosimilar competition is expected in early January for the company’s second highest-selling drug, putting greater focus on newer products' market trajectory.

By Jonathan Gardner • Oct. 15, 2024

Pfizer invests in molecular glue; Jazz, MeiraGTx shares rise on drug data

The pharma will work with Triana Biomedicines on molecular glue degraders. Elsewhere, Akeso raised $250 million and a MASH drug developer got a well-known board chair.

By BioPharma Dive staff • Oct. 15, 2024

GSK says antibody drug succeeds in testing for chronic nasal condition

The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.

By Delilah Alvarado • Oct. 14, 2024

Pfizer drug for hemophilia approved by FDA

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor. 

By Ned Pagliarulo • Oct. 14, 2024

Choosing the right hub partner: A blueprint for decision-makers

An effective drug launch requires a hub partner with key capabilities, as outlined in the 2024 Patient Services Report by CareMetx.

By Erin Kholodovsky, SVP Account Management at CareMetx • Oct. 14, 2024

Sanofi may have found a buyer for its consumer health business

The French pharmaceutical giant said it’s in negotiations to sell a controlling stake of Opella to the private equity firm CD&R, in a deal that reportedly could be worth more than $16 billion.

By Jacob Bell • Oct. 11, 2024

FDA clears Roche breast cancer drug; Turnstone lays off 60% of staff

Itovebi is part of a push by Roche to make new inroads in breast cancer. Elsewhere, Turnstone is trimming preclinical research and Gritstone bio is working on a bankruptcy deal.

By BioPharma Dive staff • Oct. 11, 2024

Ex-Pfizer execs ‘threatened’ for supporting plans to shake up company, Starboard says

In a letter to Pfizer’s board, the activist investor claimed former CEO Ian Read and CFO Frank D’Amelio were pressured to abandon a Starboard-led attempt to change the company’s direction.

By Kristin Jensen • Oct. 10, 2024

Lilly names Mount Sinai scientist as first chief AI officer

Thomas Fuchs will lead artificial intelligence initiatives across Lilly, including in drug discovery, clinical trials and manufacturing.

By Ned Pagliarulo • Oct. 9, 2024

Protein prediction wins chemistry Nobel; Alnylam submits an all-important drug application

AlphaFold’s developers were awarded science’s top prize. Elsewhere, J&J is shuttering an intriguing cancer study and Alnylam is asking for approval of a drug that could rival a Pfizer blockbuster.

By BioPharma Dive staff • Oct. 9, 2024

Using de-identified lab data to find patients, target physicians and expedite treatment

Many pharma companies are now using de-identified lab data to identify potential patients and their physicians in time to impact the patient’s treatment plan. In this Q&A, learn how lab data can be used to increase patient access.

By Madeline Naylor, DHSc, Vice President of Health Informatics, RWD, Norstella with Patrick Winniewicz, Executive Director of Healthcare Analytics Solutions, Quest Diagnostics • Oct. 9, 2024

GSK says RSV vaccine protects against disease over three seasons

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.

By Delilah Alvarado • Oct. 8, 2024

GSK’s ViiV to expand supply of HIV drug in Africa

The company is committing to make at least 2 million doses of its long-acting PrEP therapy available in low- and middle-income countries next year and in 2026.

By Delilah Alvarado • Oct. 7, 2024

Opdivo gets ‘perioperative’ approval; pharmas cut jobs in New Jersey, Ireland

Bristol Myers' immunotherapy can now be used before and after surgery in the U.S. Elsewhere, J&J, Bayer, Bristol Myers Squibb and Pfizer are trimming staff.

By BioPharma Dive staff • Oct. 4, 2024

FDA makes end of Zepbound, Mounjaro shortage official

Removal of Lilly’s in-demand drugs from the FDA’s shortage list ramps up pressure on the companies selling compounded counterparts. 

By Kristin Jensen • Oct. 3, 2024

Lilly plans $4.5B ‘foundry’ for advanced drug manufacturing

With its latest investment, Lilly is looking toward medicines of the future and new methods to produce them.

By Kristin Jensen • Oct. 2, 2024

How Roche plans to fill a projected $8B sales gap

Biosimilar competition to aging blockbusters will erode a large chunk of the pharma giant’s top line over the next few years.

By Amy Baxter • Oct. 2, 2024

The top biopharma conferences remaining in 2025

Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies' research progress. Here’s a list of conferences to watch the rest of 2025. 

By BioPharma Dive staff • Updated June 30, 2025

IGM lays off staff in autoimmune pivot; Metsera ramps up obesity drug supply

IGM is the latest biotech to focus on the potential for T cell engagers to treat inflammatory conditions. Elsewhere, Metsera signed a manufacturing deal and UCB started a first-of-its-kind trial. 

By BioPharma Dive staff • Oct. 1, 2024

Roche turns to a startup in search for new breast cancer drugs

The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to blockbuster medicines from Pfizer and Eli Lilly.

By Jonathan Gardner • Sept. 30, 2024